SAB Biotherapeutics is trading at $3.29, up 5.45% on November 4, 2026; biotech-sector strength is a possible backdrop, but no specific cause for the additional gain has been established. - XBI was up 2.13% during the regular session amid rotation into biotech. - The company is scheduled to report Q3 2026 results before market open November 5. - The results call is scheduled for 8:30 a.m. ET.